Fabrazyme Injection, Powder, Lyophilized, For Solution
NDC 58468-0041
Product Information
Fabrazyme (agalsidase beta) is a BLA-approved product labeled by Genzyme Corporation. This medication is used to treat a certain inherited disorder (Fabry disease) that causes buildup of a certain fat substance (GL-3) in some parts of your body. It is supplied as a injection, powder, lyophilized, for solution for intravenous administration. This product entry covers the primary NDC 58468-0041 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 58468-0041?
What are the uses of this product?
What are Active Ingredients of this product?
- AGALSIDASE BETA 5 mg/mL - recombinant protein for treatment of FABRY DISEASE
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- AGALSIDASE BETA (UNII: RZD65TSM9U)
- AGALSIDASE BETA (UNII: RZD65TSM9U) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MANNITOL (UNII: 3OWL53L36A)
- SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)
- SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE (UNII: 70WT22SF4B)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1804755 - agalsidase beta 35 MG Injection
- RxCUI: 1804758 - Fabrazyme 35 MG Injection
- RxCUI: 1804758 - agalsidase beta 35 MG Injection [Fabrazyme]
- RxCUI: 1804760 - agalsidase beta 5 MG Injection
- RxCUI: 1804762 - Fabrazyme 5 MG Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.